Price to FCFE (P/FCFE)
Free Cash Flow to Equity (FCFE)
Biogen Inc., FCFE calculation
US$ in thousands
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Price to FCFE Ratio, Current
Biogen Inc., current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | 144,001,404 |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in thousands) | 3,193,000) |
| FCFE per share | 22.17 |
| Current share price (P) | 273.56 |
| Valuation Ratio | |
| P/FCFE | 12.34 |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| AbbVie Inc. | 26.78 |
| Amgen Inc. | 90.83 |
| Bristol-Myers Squibb Co. | 16.29 |
| Danaher Corp. | 24.57 |
| Eli Lilly & Co. | 63.65 |
| Gilead Sciences Inc. | 24.48 |
| Johnson & Johnson | 22.11 |
| Merck & Co. Inc. | 15.39 |
| Pfizer Inc. | 17.84 |
| Regeneron Pharmaceuticals Inc. | 21.92 |
| Thermo Fisher Scientific Inc. | 21.05 |
| Vertex Pharmaceuticals Inc. | 41.05 |
| P/FCFE, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 28.45 |
| P/FCFE, Industry | |
| Health Care | 25.83 |
Based on: 10-K (reporting date: 2021-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Biogen Inc., historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 146,962,793 | 152,335,731 | 174,064,011 | 196,708,784 | 211,562,686 | |
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in thousands)2 | 3,193,000) | 5,220,400) | 6,409,100) | 5,410,900) | 2,147,300) | |
| FCFE per share3 | 21.73 | 34.27 | 36.82 | 27.51 | 10.15 | |
| Share price1, 4 | 220.17 | 263.25 | 337.24 | 333.24 | 346.00 | |
| Valuation Ratio | ||||||
| P/FCFE5 | 10.13 | 7.68 | 9.16 | 12.11 | 34.09 | |
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| AbbVie Inc. | 18.76 | — | — | — | — | |
| Amgen Inc. | 13.52 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 16.17 | — | — | — | — | |
| Danaher Corp. | 20.75 | — | — | — | — | |
| Eli Lilly & Co. | 35.17 | — | — | — | — | |
| Gilead Sciences Inc. | 12.70 | — | — | — | — | |
| Johnson & Johnson | 23.28 | — | — | — | — | |
| Merck & Co. Inc. | 18.72 | — | — | — | — | |
| Pfizer Inc. | 8.88 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 10.35 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 13.44 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 26.08 | — | — | — | — | |
| P/FCFE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 16.49 | — | — | — | — | |
| P/FCFE, Industry | ||||||
| Health Care | 17.94 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Data adjusted for splits and stock dividends.
3 2021 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 3,193,000,000 ÷ 146,962,793 = 21.73
4 Closing price as at the filing date of Biogen Inc. Annual Report.
5 2021 Calculation
P/FCFE = Share price ÷ FCFE per share
= 220.17 ÷ 21.73 = 10.13
6 Click competitor name to see calculations.